Halper Sadeh LLC Investigates Penumbra and RAPT Transactions
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1h ago
0mins
Source: Globenewswire
- Legal Investigation Launched: Halper Sadeh LLC is investigating the transaction between Penumbra, Inc. (NYSE: PEN) and Boston Scientific Corporation, involving either 3.8721 shares of Boston Scientific common stock or $374.00 in cash, potentially indicating breaches of fiduciary duties to shareholders.
- Shareholder Rights Protection: The law firm may seek increased consideration and additional disclosures for Penumbra shareholders, aiming to ensure that their legal rights are fully protected during the transaction process.
- RAPT Transaction Review: Halper Sadeh LLC is also examining the acquisition of RAPT Therapeutics, Inc. (NASDAQ: RAPT) by GSK plc at a price of $58.00 per share, which may impact shareholder interests significantly.
- Global Investor Support: Halper Sadeh LLC offers legal consultations without upfront fees, encouraging affected shareholders to reach out to discuss their rights and options, highlighting its commitment to protecting global investor interests.
Analyst Views on PEN
Wall Street analysts forecast PEN stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for PEN is 344.64 USD with a low forecast of 266.00 USD and a high forecast of 388.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
15 Analyst Rating
14 Buy
1 Hold
0 Sell
Strong Buy
Current: 359.000
Low
266.00
Averages
344.64
High
388.00
Current: 359.000
Low
266.00
Averages
344.64
High
388.00
About PEN
Penumbra, Inc. is a thrombectomy company, which is focused on developing technologies for challenging medical conditions, such as ischemic stroke, venous thromboembolism, such as pulmonary embolism, and acute limb ischemia. The Company's broad portfolio, which includes computer assisted vacuum thrombectomy (CAVT), centers on removing blood clots from head-to-toe. It focuses on developing, manufacturing and marketing novel products for use by specialist physicians and healthcare providers to drive improved clinical and health outcomes. Some of the conditions it focuses on are Pulmonary Embolism, Deep Vein Thrombosis, Acute Limb Ischemia, Ischemic Stroke, Acute Coronary Syndrome, and Clot associated with Arteriovenous Graft or Fistula. The Company sells its products to healthcare providers primarily through its direct sales organization in the United States, Europe, Canada and Australia, as well as through distributors in select international markets.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
